Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin Baigent

Showing results (91-100 of 171) with videos related to

Pageof 18
Sort By:
Circulation. Genomic and Precision Medicine|February 17, 2018
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE StudySarah Parish, Jemma C Hopewell, Michael R Hill, et al.
European Heart Journal|April 12, 2007
Anticoagulants in heart disease: current status and perspectivesRaffaele De Caterina, Steen Husted, Lars Wallentin, et al.
Clinical Kidney Journal|December 8, 2018
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY studyWilliam G Herrington, David Preiss, Richard Haynes, et al.
Kidney International|November 18, 2017
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammationBenjamin C Storey, Natalie Staplin, Richard Haynes, et al.
European Heart Journal|July 24, 2020
Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptomJemma C Hopewell, Alison Offer, Richard Haynes, et al.
Kidney International|February 4, 2018
Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapyBenjamin C Storey, Natalie Staplin, Charlie H Harper, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 25, 2015
Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)Borislava Mihaylova, Iryna Schlackow, William Herrington, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 15, 2014
The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal ProtectionWilliam Herrington, Jonathan Emberson, Natalie Staplin, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 31, 2023
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization StudyKillian Donovan, William G Herrington, Guillaume Paré, et al.
Kidney International|February 3, 2023
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitorsDaniel Chapman, Parminder K Judge, Rebecca J Sardell, et al.
Pageof 18

Showing results (91-100 of 171) with videos related to

Sort By:
Pageof 18
Circulation. Genomic and Precision Medicine|February 17, 2018
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE StudySarah Parish, Jemma C Hopewell, Michael R Hill, et al.
European Heart Journal|April 12, 2007
Anticoagulants in heart disease: current status and perspectivesRaffaele De Caterina, Steen Husted, Lars Wallentin, et al.
Clinical Kidney Journal|December 8, 2018
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY studyWilliam G Herrington, David Preiss, Richard Haynes, et al.
Kidney International|November 18, 2017
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammationBenjamin C Storey, Natalie Staplin, Richard Haynes, et al.
European Heart Journal|July 24, 2020
Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptomJemma C Hopewell, Alison Offer, Richard Haynes, et al.
Kidney International|February 4, 2018
Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapyBenjamin C Storey, Natalie Staplin, Charlie H Harper, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 25, 2015
Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)Borislava Mihaylova, Iryna Schlackow, William Herrington, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 15, 2014
The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal ProtectionWilliam Herrington, Jonathan Emberson, Natalie Staplin, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 31, 2023
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization StudyKillian Donovan, William G Herrington, Guillaume Paré, et al.
Kidney International|February 3, 2023
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitorsDaniel Chapman, Parminder K Judge, Rebecca J Sardell, et al.
Pageof 18